Antibody Drug Developability Analysis/Drugability Analysis
Antibody drug developability analysis (drugability analysis) is a key strategy used to assess the development prospects of candidate antibody drugs. This analysis is based on a comprehensive evaluation of multiple aspects of candidate antibodies, including biological activity, pharmacology, pharmacokinetics, safety, and feasibility of preparation. Through systematic developability analysis, candidate antibody drugs with potential clinical applications and commercial value are screened. This strategy is significant for narrowing the range of candidate antibody drugs, reducing development risks, and saving time and costs. At the same time, this analysis strategy also helps predict the performance of drugs in clinical trials and market promotion stages, providing guidance for clinical translation and commercialization.
Antibody drug analysis based on LC-MS
Mass spectrometry plays a key role in the developability analysis of antibody drugs:
• Structure identification of antibody drugs:Through mass spectrometry, the primary structure of antibody drugs can be accurately analyzed. Peptide fingerprinting and tandem mass spectrometry analysis can accurately identify amino acid sequences and detect key post-translational modifications such as glycosylation and phosphorylation.
• Post-translational modification analysis:Many functions and stability of antibody drugs are related to their post-translational modifications. Mass spectrometry can be used to identify and quantify these modifications to understand their impact on drug properties.
• Antibody assembly and isoform analysis:Through mass spectrometry analysis, the assembly state of antibodies and the formation of isoforms can be analyzed, which is crucial for evaluating the stability and biological activity of drugs.
• Molecular weight analysis:Mass spectrometry can be used to confirm the molecular weight and isotopic pattern of antibody drugs, which helps ensure the quality and consistency of the drug.
BaiTaiPark BiotechnologyThroughCNAS/ISO9001 dual quality system certification, the company based onThermo's Orbitrap Fusion Lumos mass spectrometer combined with Nano-LC technology,provides you withantibody drug developability analysis (drugability analysis)services, offering comprehensive characterization of candidate antibody proteins to aid the development of novel antibody drugs. Welcome to consult for free!
Bilingual project report
In the technical report, BaiTaiPark will provide you with a detailed bilingual technical report in both Chinese and English, including:
1. Experimental procedures (Chinese and English)
2. Relevant mass spectrometry parameters (Chinese and English)
3. Detailed information on antibody drug developability analysis/drugability analysis
4. Mass spectrometry images
5. Raw data
One-stop service for antibody drug developability analysis/drugability analysis
You only need to place an order - send samples
BaiTaiPark one-stop service completes: sample processing - machine analysis - data analysis - project report
Related services
Antibody-drug conjugates (ADCs) analysis
How to order?
